波士顿 - Praxis Precision Medicines Inc. (NASDAQ: PRAX) ...

康乐卫士表示，本次九价HPV疫苗（女性适应症）国内Ⅲ期临床试验首次分析结果主要基于截至第11次访视的主要终点病例数据，后续相关各方还需根据方案及统计分析计划的规定开展全面深入分析，并完成临床试验总结报告。公司将同步开展 九价HPV疫苗 上市许可申报资料的撰写工作，并将积极与药监部门沟通，争取基于PI12终点数据尽早提交九价HPV疫苗（女性适应症）国内生物制品许可申请。

The IDMC’s review identified no significant safety concerns and recommended proceeding with enrollment in the second cohort. AMT-162 is an investigational AAVrh10-based gene therapy that ...

Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.

Results of the Planned Interim Analysis and Update on Topline Read-out for the Essential3 Program: The Independent Data Monitoring Committee (IDMC) overseeing the interim analysis of Study 1 of the ...